IM Primary immunisation Adult ≥19 yr Havrix 1440 Adult 1 mL single dose in deltoid area. Childn & adolescent 1-18 yr Havrix 720 Junior 0.5 mL single dose in deltoid area (in the antero-lateral part of the thigh in young childn). Booster vaccination After primary vaccination w/ Havrix 1440 Adult or Havrix 720 Junior, booster dose should be given between 6 mth & 5 yr, but preferably between 6 & 12 mth after primary dose.
Not to be inj SC, intravascularly, intradermally or in the gluteal region. Not for prevention against infection caused by other agents eg, HBV, HCV, hepatitis E virus or other pathogens infecting the liver. Postpone vaccination in patients w/ acute severe febrile illness. Thrombocytopenia or bleeding disorder; syncope. Patients w/ impaired immune system. Patients undergoing haemodialysis. Pregnancy & lactation.
Irritability; headache; inj site pain & redness, fatigue. Loss of appetite; drowsiness; GI symptoms eg, diarrhoea, nausea, vomiting; malaise, fever (≥37.5°C), inj site swelling or induration.
Sign Out
